- Home
- HNNA vs ANL Comparison
HNNA vs ANL Comparison
Compare HNNA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNNA
- ANL
- Stock Information
- Founded
- HNNA 1989
- ANL 2004
- Country
- HNNA United States
- ANL Cayman Islands
- Employees
- HNNA N/A
- ANL N/A
- Industry
- HNNA Investment Managers
- ANL
- Sector
- HNNA Finance
- ANL
- Exchange
- HNNA Nasdaq
- ANL Nasdaq
- Market Cap
- HNNA 82.4M
- ANL 79.0M
- IPO Year
- HNNA N/A
- ANL 2023
- Fundamental
- Price
- HNNA $10.99
- ANL $2.00
- Analyst Decision
- HNNA
- ANL Strong Buy
- Analyst Count
- HNNA 0
- ANL 2
- Target Price
- HNNA N/A
- ANL $9.00
- AVG Volume (30 Days)
- HNNA 23.5K
- ANL 27.5K
- Earning Date
- HNNA 05-07-2025
- ANL 05-06-2025
- Dividend Yield
- HNNA 5.00%
- ANL N/A
- EPS Growth
- HNNA 75.66
- ANL N/A
- EPS
- HNNA 1.12
- ANL N/A
- Revenue
- HNNA $33,210,000.00
- ANL $5,000,000.00
- Revenue This Year
- HNNA N/A
- ANL N/A
- Revenue Next Year
- HNNA N/A
- ANL N/A
- P/E Ratio
- HNNA $9.24
- ANL N/A
- Revenue Growth
- HNNA 38.27
- ANL N/A
- 52 Week Low
- HNNA $6.60
- ANL $1.69
- 52 Week High
- HNNA $13.88
- ANL $14.90
- Technical
- Relative Strength Index (RSI)
- HNNA 60.98
- ANL 49.37
- Support Level
- HNNA $9.46
- ANL $1.69
- Resistance Level
- HNNA $10.78
- ANL $2.18
- Average True Range (ATR)
- HNNA 0.73
- ANL 0.14
- MACD
- HNNA 0.19
- ANL 0.01
- Stochastic Oscillator
- HNNA 99.61
- ANL 62.24
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.